Legal & General Group
NRIX icon

Legal & General Group’s Nurix Therapeutics NRIX Stock Holding History

Legal & General Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.1M Sell
70,765
-14,224
-17% -$236K ﹤0.01% 2111
2025
Q4 		$1.61M Buy
84,989
+2,072
+2% +$29.8K ﹤0.01% 2060
2025
Q3 		$766K Buy
82,917
+20,497
+33% +$213K ﹤0.01% 2317
2025
Q2 		$711K Buy
62,420
+3,801
+6% +$41.1K ﹤0.01% 2339
2025
Q1 		$696K Sell
58,619
-1,798
-3% -$30.1K ﹤0.01% 2300
2024
Q4 		$1.14M Buy
60,417
+518
+0.9% +$11.9K ﹤0.01% 2194
2024
Q3 		$1.35M Buy
59,899
+9,019
+18% +$204K ﹤0.01% 2124
2024
Q2 		$1.06M Buy
50,880
+44,138
+655% +$687K ﹤0.01% 2177
2024
Q1 		$99.1K Sell
6,742
-154
-2% -$1.66K ﹤0.01% 2738
2023
Q4 		$71.2K Sell
6,896
-25,083
-78% -$172K ﹤0.01% 2776
2023
Q3 		$251K Sell
31,979
-559
-2% -$5.1K ﹤0.01% 2668
2023
Q2 		$325K Buy
32,538
+17,932
+123% +$183K ﹤0.01% 2603
2023
Q1 		$130K Buy
14,606
+610
+4% +$6.36K ﹤0.01% 2721
2022
Q4 		$154K Buy
13,996
+717
+5% +$8.65K ﹤0.01% 2702
2022
Q3 		$173K Buy
13,279
+1,106
+9% +$17.5K ﹤0.01% 2675
2022
Q2 		$154K Buy
12,173
+3,216
+36% +$36.5K ﹤0.01% 2731
2022
Q1 		$126K Sell
8,957
-10
-0.1% -$178 ﹤0.01% 2807
2021
Q4 		$259K Buy
8,967
+53
+0.6% +$1.61K ﹤0.01% 2609
2021
Q3 		$267K Buy
8,914
+5,241
+143% +$162K ﹤0.01% 2597
2021
Q2 		$98K Buy
3,673
+747
+26% +$21.9K ﹤0.01% 2743
2021
Q1 		$90K Buy
2,926
+1,248
+74% +$47.2K ﹤0.01% 2647
2020
Q4 		$55K Buy
1,678
+434
+35% +$14.4K ﹤0.01% 2772
2020
Q3 		$43K Buy
+1,244
New +$31.4K ﹤0.01% 2746

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Legal & General Group's NRIX Position: Q1 2026 in Review

Legal & General Group reduced its Nurix Therapeutics (NRIX) stake by 17% in Q1 2026, selling an estimated $236K and leaving 70,765 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2111.

Legal & General Group first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $1.61M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Legal & General Group held 70,765 shares of Nurix Therapeutics worth $1.1M as of Q1 2026.
  • Legal & General Group sold 14,224 Nurix Therapeutics shares in Q1 2026, an estimated $236K.
  • Nurix Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2111 holding.
  • Legal & General Group first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Legal & General Group's Nurix Therapeutics position peaked at $1.61M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.